Lyora Therapeutics
Lyora Therapeutics, Inc.
Lyra Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing groundbreaking therapies specifically for chronic rhinosinusitis (CRS), a prevalent inflammatory condition affecting the nasal passages and sinuses. By leveraging innovative technologies, Lyra aims to provide effective solutions for CRS patients who often endure ineffective treatments and potentially invasive surgeries.
Products & Team
LYR-210
LYR-210 is a bioresorbable nasal implant specifically designed to deliver continuous anti-inflammatory medication for up to six months directly to the sinonasal passages. This innovative solution targets chronic rhinosinusitis patients who have not yet undergone sinus surgery, aiming to alleviate their symptoms effectively without requiring invasive interventions.
LYR-210 addresses the significant problem of inadequate treatment options for patients with chronic rhinosinusitis by providing a sustained and effective alternative to existing therapies, reducing the need for surgeries.
Many CRS patients face significant challenges, including inadequate treatment options that fail to alleviate symptoms, resulting in a cycle of ineffective treatments and the potential necessity for invasive sinus surgeries.